-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, McMoyTQE6W2eUw+H68GPm8qDdW4EA91zhdBLz7UcA071fuc15AF2+2QGIaq/yPCU naKzwOG/qWAmAjoqvdHjMA== 0000912057-01-529985.txt : 20010824 0000912057-01-529985.hdr.sgml : 20010824 ACCESSION NUMBER: 0000912057-01-529985 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010822 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20010823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IBIS TECHNOLOGY CORP CENTRAL INDEX KEY: 0000855182 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] IRS NUMBER: 042987600 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23150 FILM NUMBER: 1721709 BUSINESS ADDRESS: STREET 1: 32 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787774247 MAIL ADDRESS: STREET 1: 32 CHERRY HILL DR STREET 2: 32 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 a2057918z8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): AUGUST 22, 2001 IBIS TECHNOLOGY CORPORATION --------------------------- (Exact name of registrant as specified in its charter) MASSACHUSETTS 0-23150 04-2987600 - -------------- ------------- ------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation)
32 CHERRY HILL DRIVE, DANVERS, MASSACHUSETTS 01923 ------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (978) 777-4247 ITEM 5. OTHER EVENTS. On August 22, 2001, Ibis Technology Corporation publicly disseminated a press release announcing the election of Dr. Yuri Erokhin as its Vice President of Wafer Technology. Ibis also announced the resignations of two Directors, Geoffrey Ryding and Peter Rose, who resigned to, together, pursue other business opportunities. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibit. 99.1 Press Release dated August 22, 2001. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IBIS TECHNOLOGY CORPORATION (Registrant) Date: August 22, 2001 /s/ Debra L. Nelson --------------------------------------------- Debra L. Nelson, Chief Financial Officer EXHIBIT INDEX
EXHIBIT SEQUENTIAL NUMBER DESCRIPTION PAGE NUMBER 99.1 Press Release dated 5 August 22, 2001
EX-99.1 3 a2057918zex-99_1.txt EX-99.1 EXHIBIT 99.1 CONTACT: Debra L. Nelson Bill Monigle Chief Financial Officer IR Counsel Ibis Technology Corporation (603) 424-1184 (978) 777-4247 FOR IMMEDIATE RELEASE IBIS TECHNOLOGY ANNOUNCES THE ELECTION OF DR. YURI EROKHIN AS VICE PRESIDENT OF WAFER TECHNOLOGY DANVERS, Mass, Aug. 22, 2001--Ibis Technology Corporation (Nasdaq:IBIS), the leading provider of SIMOX-SOI implantation equipment and wafers to the worldwide semiconductor industry, today announced the election of Dr. Yuri Erokhin as its Vice President of Wafer Technology. Ibis also announced today the resignations of two Directors, Geoffrey Ryding and Peter Rose, who resigned to, together, pursue other business opportunities. Dr. Yuri Erokhin joined Ibis in October 2000 as Director of Wafer Technology, after a 5-year career at Eaton Corporation (now Axcelis Technologies) where he was Director of Process Technology in the Implant Systems Division. Dr. Erokhin led the department responsible for process development, worldwide applications support and equipment demonstrations to prospective customers. Prior to Axcelis, Dr. Erokhin was a Research Associate at North Carolina State University investigating formation of silicided shallow junction and process-induced crystal defects in silicon. He holds a Ph.D. degree in Microelectronics Technology. Martin J. Reid, president and chief executive officer of Ibis Technology stated, "I am pleased to announce Dr. Yuri Erokhin's appointment as Vice President of Wafer Technology. Yuri has an extensive range of expertise in ion implantation technology, CMOS device physics and Si material science. I am confident that, in this new role, his skills and leadership abilities will contribute to maintaining our technology leadership position in the industry. SOI technology is being adopted by chip makers at an increasing pace, and Yuri will play a major role in assuring that our products continue to contribute to our customers' ability to keep integrated circuit advancements on track with Moore's law." Reid added, "I also wish to thank Geoff Ryding and Peter Rose for their work as directors. Their contributions are greatly appreciated." ABOUT IBIS TECHNOLOGY Ibis Technology Corporation is the leading provider of SIMOX-SOI (Separation by Implanted Oxygen-Silicon-On-Insulator) wafers and equipment for the worldwide semiconductor industry. The company is headquartered in Danvers, Massachusetts and maintains an office in Aptos, California. Information about Ibis Technology Corporation and SIMOX-SOI is available on Ibis' World Wide Web site at WWW.IBIS.COM. -MORE- IBIS ANNOUNCES THE ELECTION OF EROKHIN AS VICE PRESIDENT.....PAGE 2 "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: This release may contain forward-looking statements that are subject to certain risks and uncertainties including statements regarding advances in SIMOX wafer technology, the potential improvements to and development of next generation SIMOX-SOI wafer products and the adoption of SOI technology by chip makers. Such statements are based upon management's current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements, including, but not limited to, product demand and market acceptance risks, general economic conditions, the impact of competitive products, technologies and pricing, the impact of rapidly changing technology, equipment capacity and supply constraints or difficulties, limitations on the ability to protect the Company's patents and proprietary technology, the Company's limited history with regard to sales of implanters, the cyclical nature of the semiconductor industry, and other risks described in the Company's Securities and Exchange Commission filings. All information set forth in this press release is as of August 22, 2001, and Ibis undertakes no duty to update this information unless required by law. ### -----END PRIVACY-ENHANCED MESSAGE-----